- Home
- CHI vs GHRS Comparison
CHI vs GHRS Comparison
Compare CHI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | GHRS |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHI | GHRS |
|---|---|---|
| Price | $13.19 | $22.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 149.1K | ★ 231.7K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.10 | $11.32 |
| 52 Week High | $13.22 | $25.94 |
Technical Indicators
Market Signals| Indicator | CHI | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 54.61 |
| Support Level | $10.40 | $12.65 |
| Resistance Level | N/A | $22.88 |
| Average True Range (ATR) | 0.23 | 1.69 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 98.87 | 42.37 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.